Cis-aconitate Renal Disease Marker Detection via CE-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current renal disease diagnostic methods are inadequate for accurately detecting renal diseases, especially in the early stages, and fail to effectively evaluate renal function beyond glomerular filtration rate, leading to incomplete symptom assessment and unknown aggravation mechanisms.
Innovation Solution
The method involves using capillary electrophoresis mass spectrometry (CE-MS) to analyze plasma substances and identify cis-aconitate as a novel renal disease marker, which correlates with estimated glomerular filtration rate (eGFR) and can detect renal disease severity, enabling early stage detection and screening for prophylactic/therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional renal disease marker substances such as creatinine are used, then glomerular filtration rate can be assessed, but early stage renal disease cannot be accurately detected due to creatinine blind GFR area
Solution Approach 1:
The invention changes the measurement parameter from creatinine concentration to cis-aconitate concentration. Cis-aconitate shows a linear correlation with eGFR across the entire range including early stages, whereas creatinine has a blind area in early stages. This parameter change enables accurate detection of early stage renal disease without the blind spot that limits creatinine-based methods.
2Adaptability or versatility
If existing marker substances are used, then some renal function can be evaluated, but various symptoms of renal failure cannot be evaluated in an integrated fashion
Solution Approach 1:
Cis-aconitate serves as a universal marker that reflects multiple aspects of renal function including glomerular filtration rate and tubular function. The linear correlation between cis-aconitate concentration and eGFR provides comprehensive information about renal function across different disease stages and types, enabling integrated evaluation of various renal symptoms that cannot be achieved with single-function markers like creatinine.
3Reliability
If conventional diagnostic methods are used, then established renal diseases can be detected, but novel renal disease marker substances remain unnoticed
Solution Approach 1:
The invention replaces conventional mechanical/chemical diagnostic methods with capillary electrophoresis mass spectrometry (CE-MS). This advanced analytical technique enables comprehensive profiling of plasma substances and identification of novel markers like cis-aconitate that show linear correlation with eGFR. The CE-MS system provides both reliable detection of known markers and discovery of new markers through its ability to analyze multiple substances simultaneously with high precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate detection of renal diseases not identified by conventional methods, provides early stage detection, and efficiently screens for new therapeutic agents, improving renal disease management and reducing medical costs.
Implementation Method 1
capillary electrophoresis mass spectrometry (CE-MS) is a recently developed new system, which enables simultaneous measurement of 500 or more kinds of substances from a small amount of sample
Data Source
AI summary
The present invention relates to a method for diagnosing, and treating renal disease in a patient by having a test performed for detecting or quantifying one or more renal disease markers present in a test blood sample from the patient; and administering treatment to improve renal function. In particular embodiments, the test performed quantifies cis-aconitate, and the patient is identified as having the renal disease when a concentration of cis-aconitate present in the patient's test blood sample is higher than that of a control. Methods of the present invention can allow diagnosis and treatment of patients with early stage renal disease, such as early stage renal failure. Another aspect of the present invention relates to methods for screening for a prophylactic/therapeutic agent for treating renal disease using one or more renal disease markers.